Analysis of episodes of care in a perfluorooctanesulfonyl fluoride production facility

Journal of Occupational and Environmental Medicine

Volumn 46, Issue 8, 2004, Pages 837-846

  Olsen, Geary W ^a   Burlew, Michele M ^a   Marshall, Julia C ^b   Burris, Jean M ^a   Mandel, Jeffrey H ^a  

^a 3M COMPANY   (United States)

^b Ingenix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PERFLUORO COMPOUND; PERFLUOROOCTANESULFONYL FLUORIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BILIARY TRACT DISEASE; BLADDER CANCER; CHEMICAL INDUSTRY; COLON POLYP; COLORECTAL TUMOR; CONTROLLED STUDY; CYSTITIS; FEMALE; GENITAL SYSTEM DISEASE; HUMAN; LIPID METABOLISM; LIVER DISEASE; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; MELANOMA; METABOLIC DISORDER; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; PERINATAL MORBIDITY; PREGNANCY; RECURRENT DISEASE; REPRODUCTION; THYROID DISEASE; UNITED STATES;

ADULT; ALABAMA; ALKANESULFONIC ACIDS; CHEMICAL INDUSTRY; EPISODE OF CARE; FEMALE; FLUORIDES; FLUOROCARBONS; HUMANS; MALE; MIDDLE AGED; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; OCTANOIC ACIDS; WORKPLACE;

NON-A, NON-B HEPATITIS VIRUS;

EID: 4143095922     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jom.0000135546.70469.87     Document Type: Article

References (46)

1. Health and Environmental Assessment of Perfluorooctane Sulfonic Acid and Its Salts. St. Paul, MN: 3M Co; 2003. US EPA docket AR-226-1486.
2. Hansen KJ, Clemen LA, Ellefson ME, et al. Compound-specific quantitative characterization of organic fluorochemicals in biological matrices. Environ Sci Technol. 2001;35:766-770.
3. Olsen GW, Hansen KJ, Stevenson LA, et al. Human donor liver and serum concentrations of perfluorooctanesulfonate and other perfluorochemicals. Environ Sci Technol. 2003;37:888-891.
4. Olsen GW, Church TR, Miller JP, et al. Perfluorooctanesulfonate and other fluorochemicals in the serum of American Red Cross adult blood donors. Environ Health Perspect. 2003;111:1892-1901.
5. Olsen GW, Church TR, Larson EB, et al. Serum concentrations of perflurooctanesulfonate and other fluorochemicals in an elderly population from Seattle, Washington. Chemosphere. 2004;54:1599-1611.
6. Olsen GW, Church TR, Hansen KJ, et al. Quantitative evaluation of perflurooctanesulfonate (PFOS) and other fluorochemicals in the serum of children. J Child Health. 2004;2:53-76.
7. Giesy JP, Kannan K. Global distribution of perfluorooctane sulfonate in wildlife. Environ Sci Technol. 2001;35:1339-1342.
8. Kannan K, Koistinen J, Beckmen K, et al. Accumulation of perfluorooctane sulfonate in marine mammals. Environ Sci Technol. 2001;35:1593-1598.
9. Kannan K, Franson JC, Bowerman WW, et al. Perfluorooctane sulfonate in fisheating water birds including bald eagles and albatrosses. Environ Sci Technol. 2001;35:3065-3070.
10. Kannan K, Corsolini S, Falandysz J, et al. Perfluorooctanesulfonate and related fluorinated hydrocarbons in marine mammals, fishes, and birds from coasts of the Baltic and Mediterranean Seas. Environ Sci Technol. 2002;36:3210-3216.
11. US Environmental Protection Agency. Perfluorooctane sulfonates: significant new use rule; final rule. Federal Register. 2002;67:72854-72867.
12. Seacat AM, Thomford PJ, Hansen KJ, et al. Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol Sci. 2002;68:249-264.
13. Seacat AM, Thomford PJ, Hansen KJ, et al. Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology. 2002;183:117-131.
14. Seacat AM, Thomford PJ, Butenhoff JL. Terminal observations in Sprague-Dawley rats after lifetime dietary exposure to potassium perfluorooctanesulfonate [Abstract]. Toxicologist. 2002;66:185.
15. Case MT, York RG, Christian MS. Rat and rabbit oral developmental toxicology studies with two perfluorinated compounds. Int J Toxicol. 2001;20:101-109.
16. Butenhoff J, York R, Seacat A, et al. Perfluorooctanesulfonate-induced perinatal mortality in rat pups is associated with a steep dose-response [Abstract]. Toxicologist. 2002;66:25.
17. Thibodeaux JR, Hanson RG, Rogers JM, et al. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. I: Maternal and prenatal evaluations. Toxicol Sci. 2003;74:369-381.
18. Lau C, Thibodeaux JR, Hanson RG, et al. Exposure to perfluorooctane sulfonate during pregnancy in rat and mouse. II: postnatal evaluation. Toxicol Sci. 2003;74:382-392.
19. Haughom B, Spydevold O. The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctanesulphonic acid (PFOSA) and clofibric acid. Biochemica et Biophysica Acta. 1992;1128:65-72.
20. Ikeda T, Fukuda K, Mori I, et al. Induction of cytochrome P-450 and peroxisome proliferation in rat liver by perfluorinated octanesulfonic acid. In: Fahmi HD, Sies H, eds. Peroxisomes in Biology and Medicine. New York: Springer Verlag; 1987:304-308.
21. Berthiaume JM, Wallace KB. Perfluorooctanoate, perfluorooctanesulfonate and N-ethyl perfluorooctanesulfonamido ethanol:peroxisome proliferation and mitochondrial biogenesis. Toxicol Lett. 2002;129:23-32.
22. Luebker DJ, Hansen KJ, Bass N, et al. Interactions of fluorochemicals with rat fatty acid-binding protein. Toxicology. 2002;176:175-185.
23. Starkov AA, Wallace KB. Structural determinants of fluorochemical-induced mitochondrial dysfunction. Toxicol Sci. 2002;66:244-252.
24. Hu W, Jones PD, Upham BL, et al. Comparisons among perfluorinated compounds of effects on gap junctional intercellular communication. Toxicol Sci. 2002;68:429-436.
25. Alexander BH, Olsen GW, Burris JM, et al. Mortality study of workers employed at a perfluorooctanesulfonyl fluoride manufacturing facility. Occup Environ Med. 2003;60:792-799.
26. Olsen GW, Burris JM, Mandel JH, et al. Serum perfluorooctane sulfonate and hepatic and lipid clinical chemistry tests in fluorochemical production employees. J Occup Environ Med. 1999;41:799-806.
27. Olsen GW, Logan PW, Hansen KJ, et al. An occupational exposure assessment of a perfluorooctanesulfonyl fluoride production site. I. Biomonitoring. Am Ind Hyg Assoc J. 2003;63:651-659.
28. Olsen GW, Burris JM, Burlew MM, et al. Epidemiologic assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate (PFOA) concentrations and medical surveillance examinations. J Occup Environ Med. 2003;45:260-270.
29. Ellefson ME. Solubility Study of Perfluorooctanesulfonate (PFOS), SD-018 and Perfluorooctanesulfonamide (FOSA), SE-27 in Male/Female Human Urine. St. Paul, MN: 3M Co; 2001. US EPA public docket AR-226-1030a007.
30. Cohen SM. Urinary bladder carcinogenesis. Toxicol Pathol. 1998;26:121-127.
31. Hornbrook MC, Hurtado A, Johnson R. Health care episodes: definition, measurement and use. Med Care Rev. 1985;42:163-218.
32. Wingert TD, Kralewski JE, Lindquist TJ, et al. Constructing episodes of care from encounter and claims data: some methodological issues. Inquiry. 1995;32:430-443.
33. Dang DK, Pont JM, Portnoy MA. Episode treatment groups: an illness classification and episode building system. Part I. Med Interface. 1996;9:118-122.
34. Dang DK, Pont JM, Portnoy MA. Episode treatment groups: an illness classification and episode building system. Part II. Med Interface. 1996;9:122-128.
35. Rosen AK, Mayer-Oakes A. Episodes of care: theoretical frameworks versus current operational realities. Journal of Quality Improvement. 1999;25:111-128.
36. Olsen GW, Logan PW, Simpson CA, et al. Fluorochemical Exposure Assessment of Decatur Chemical and Film Plant Employees. St. Paul, MN: 3M Co; August 11, 1999. US EPA docket AR-226-0950.
37. Tsai SP, Wen CP. A review of methodological issues of the standardized mortality ratio (SMR) in occupational cohort studies. Int J Epidemiol. 1986;15:8-21.
38. Ederer F, Mantel N. Confidence limits on the ratio of two Poisson variables. Am J Epidemiol. 1974;100:165-167.
39. Diem K, Lenter K, eds. Documenta Geigy Scientific Tables, 7th ed. Basel, Switzerland: Ciba-Geigy Limited; 1967.
40. Olsen GW, Burlew MM, Hocking BB, et al. An Epidemiologic Analysis of Episodes of Care of 3M Decatur Chemical and Film Plant Employees, 1993-1998. St. Paul, MN: 3M Co; 2001. US EPA docket AR-226-1030a021.
41. Hiatt RA. HIPAA. The end of epidemiology, or a new social contract? Epidemiology. 2003;14:637-639.
42. Burris JM, Lundberg JK, Olsen GW, et al. Interim Report. Determination of Serum Half-Lives of Several Fluorochemicals. St. Paul, MN: 3M Co. US EPA docket AR-226-1086.
43. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43-46.
44. Silverman DT, Morrison AS, Devesa SS. Bladder cancer. In: Schottenfeld D, Fraumeni JF, eds. Cancer Epidemiology and Prevention. New York: Oxford University Press; 1996:1156-1179.
45. Schottenfeld D, Winawer SJ. Cancers of the large intestine. In: Schottenfeld D, Fraumeni JF, eds. Cancer Epidemiology and Prevention. New York: Oxford University Press; 1996:813-840.
46. Ross RK, Schottenfeld D. Prostate cancer. In: Schottenfeld D, Fraumeni JF, eds. Cancer Epidemiology and Prevention. New York: Oxford University Press; 1996:1180-1206.